Cancer Supportive Care Drugs Global Market Report 2024

The cancer supportive care drugs market size has grown steadily in recent years. It will grow from $19.93 billion in 2023 to $20.83 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. During the historical period, growth can be attributed to several factors, including the rising geriatric population, increasing prevalence of chemotherapy, growing demand for antiemetics, a preference for online pharmacies and drug stores, increased awareness of supportive care, greater adoption of personalized medicine, and an increasing emphasis on palliative care.

The cancer supportive care drugs market size is expected to see grown steadily in the next few years. It will grow to $24.97 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth during the forecast period can be linked to increased awareness of the adverse effects of cancer treatment, a rise in breast cancer cases among females, the availability of tailored medication plans, the demand for online doctor consultations, an improved supply chain in the pharmaceutical sector, and a growing population of cancer survivors. Significant trends expected in the forecast period include advancements in targeted therapies, the integration of biobehavioral interventions, the implementation of survivorship care plans, the incorporation of nutritional support, advancements in pain management strategies, and the implementation of symptom monitoring platforms.

The improved survival rate for cancer patients is anticipated to drive the growth of the cancer supportive care drugs market moving forward. The cancer survival rate refers to the percentage of individuals who survive a specific type of cancer for a designated period, typically five years, after diagnosis. These survival rates are primarily influenced by early detection, advances in treatment, access to quality healthcare, the patient's overall health, the type and stage of cancer, and socioeconomic factors. Cancer supportive care drugs play a crucial role in enhancing survival rates by managing side effects such as pain, nausea, and anemia, enabling patients to better tolerate their treatments and complete their full course of therapy, which can lead to improved outcomes. For example, as of January 2022, the National Cancer Institute, a US-based government agency, projects a 24.4% increase in the number of cancer survivors over the next ten years, reaching 22.5 million by 2032. Thus, the improved survival rate of cancer patients is fueling the growth of the cancer supportive care drugs market.

Major companies in the cancer supportive care drugs market are developing combination therapies to address the complexity and challenges of cancer treatment. Combination therapies strategically use two or more therapeutic agents to target different aspects of cancer growth and survival, aiming to achieve deeper and more durable responses compared to monotherapy. For instance, in November 2023, Merck, a US-based pharmaceutical company, received approval from the Food and Drug Administration, a US-based federal agency, for KEYTRUDA, an anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for treating patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). The combination therapy showed promising results in improving overall survival and providing a new treatment option for patients with this challenging condition.

In March 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Ambrx Biopharma Inc. for $2 billion. The acquisition enhances Johnson & Johnson's capabilities in the design and development of targeted oncology therapeutics, particularly in cancer supportive care drugs. This strategic move underscores Johnson & Johnson's commitment to expanding its oncology portfolio, especially in prostate cancer research, and strengthening its capabilities in developing next-generation antibody-drug conjugates (ADCs). Ambrx Biopharma Inc. is a US-based biotechnology company that develops cancer supportive care drugs, including next-generation ADCs.

Major companies operating in the cancer supportive care drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, F Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc, Fagron Group, Heron Therapeutics Inc., Athenex Inc., Acrotech Biopharma LLC.

North America was the largest region in the cancer supportive care drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer supportive care drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Supportive care drugs for cancer play a crucial role in managing the adverse effects and symptoms associated with cancer treatments, significantly enhancing the quality of life for patients. These medications effectively address issues such as pain, nausea, anemia, and psychological stress, enabling patients to better tolerate their cancer therapies. By offering comprehensive symptom relief, supportive care drugs empower patients to maintain their strength and well-being throughout their treatment journey.

The primary categories of cancer supportive care drugs include erythropoiesis stimulating agents, granulocyte colony stimulating factors, antiemetics, bisphosphonates, opioids, nonsteroidal anti-inflammatory drugs, and others. Erythropoiesis-stimulating agents (ESAs) are a specific class of drugs designed to stimulate the production of red blood cells (erythropoiesis) in the bone marrow. These drugs find applications in various cancer types such as breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, among others, and are distributed through various channels including hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, and others.

The cancer supportive care drugs market research report is one of a series of new reports that provides cancer supportive care drugs market statistics, including cancer supportive care drugs industry global market size, regional shares, competitors with a cancer supportive care drugs market share, detailed cancer supportive care drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cancer supportive care drugs industry. This cancer supportive care drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer supportive care drugs market consists of the sale of analgesics, hematopoietic growth factors, bone modifying agents, corticosteroids, appetite stimulants, anti-diarrheal and laxatives, anti-anxiety and antidepressant medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.